Clinical trials in advanced stage lung cancer: a survey of patients’ opinion about their treatment

Background: The major aim of this study was to investigate what patients with advanced stage lung cancer, enrolled in a clinical trial, thought about their treatment. We also wanted to investigate if there exist any characteristics that could influence patients’ opinion about the clinical trial. Patients and methods: Over the period from June 2008 to June 2009, 59 eligible patients were enrolled in this study. The major inclusion criteria were: participation in a clinical trial, previously treated advanced stage lung cancer, and good per- formance status (ECOG 0-2). All patients were asked to answer a questionnaire designed to investigate their impres- sions about participation in a clinical trial. The questionnaire was deposited in a sealed box which was opened at the end of the study. We investigated a possible influence of age, gender, education, lung cancer stage, chemotherapy line and tumor type on the patients' opinion about some aspects of the clinical trial. Results: The majority of the patients were aware they were participating in the clinical trial and a significant number of them were very satisfied with the treatment. Of the investi- gated factors, only the level of education had a statistically significant influence on some of the questions raised in the questionnaire. Conclusions: Patients participating in clinical trials are satis- fied with their treatment, ready to proceed with it and would recommend it to other patients. It depends mainly on health professionals to maintain this level of confidence and justify their trust.

Download Full-text

“EXHALE”: exercise as a strategy for rehabilitation in advanced stage lung cancer patients: a randomized clinical trial comparing the effects of 12 weeks supervised exercise intervention versus usual care for advanced stage lung cancer patients

BMC Cancer ◽

10.1186/1471-2407-13-477 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 21

Author(s):

Morten Quist ◽

Seppo W Langer ◽

Mikael Rørth ◽

Karl Bang Christensen ◽

Lis Adamsen

Keyword(s):

Lung Cancer ◽

Clinical Trial ◽

Usual Care ◽

Cancer Patients ◽

Exercise Intervention ◽

Advanced Stage ◽

Lung Cancer Patients ◽

Supervised Exercise ◽

Advanced Stage Lung Cancer ◽

Stage Lung Cancer

Download Full-text

Clinical trials in advanced stage lung cancer: a survey of patients' opinion about their treatment

Multidisciplinary Respiratory Medicine ◽

10.1186/2049-6958-6-1-20 ◽

2011 ◽

Vol 6 (1) ◽

pp. 20 ◽

Cited By ~ 3

Author(s):

Bojan Zaric ◽

Branislav Perin ◽

Aleksandra Ilic ◽

Ivan Kopitovic ◽

Jovan Matijasevic ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Trials ◽

Advanced Stage ◽

Advanced Stage Lung Cancer ◽

Stage Lung Cancer

Download Full-text

“Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”

BMC Cancer ◽

10.1186/s12885-021-08084-0 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Brett C. Bade ◽

Geliang Gan ◽

Fangyong Li ◽

Lingeng Lu ◽

Lynn Tanoue ◽

...

Keyword(s):

Quality Of Life ◽

Physical Activity ◽

Lung Cancer ◽

Randomized Trial ◽

Cancer Biomarkers ◽

Advanced Stage ◽

Home Based ◽

Advanced Stage Lung Cancer ◽

Stage Lung Cancer

Abstract Background Lung cancer survivors need more options to improve quality of life (QoL). It is unclear to what extent patients with advanced stage disease are willing to participate in home-based physical activity (PA) and if these interventions improve QoL. The goal of our study was to determine interest in participating in our 3-month home-based walking regimen in patients with advanced stage lung cancer. We used a randomized design to evaluate for potential benefit in PA and patient-reported outcomes. Methods We performed an open-label, 1:1 randomized trial in 40 patients with stage III/IV non-small cell lung cancer (NSCLC) evaluating enrollment rate, PA, QoL, dyspnea, depression, and biomarkers. Compared to usual care (UC), the intervention group (IG) received an accelerometer, in-person teaching session, and gain-framed text messages for 12 weeks. Results We enrolled 56% (40/71) of eligible patients. Participants were on average 65 years and enrolled 1.9 years from diagnosis. Most patients were women (75%), and receiving treatment (85%) for stage IV (73%) adenocarcinoma (83%). A minority of patients were employed part-time or full time (38%). Both groups reported low baseline PA (IG mean 37 (Standard deviation (SD) 46) vs UC 59 (SD 56) minutes/week; p = 0.25). The IG increased PA more than UC (mean change IG + 123 (SD 212) vs UC + 35 (SD 103) minutes/week; p = 0.051)). Step count in the IG was not statistically different between baseline (4707 step/day), week 6 (5605; p = 0.16), and week 12 (4606 steps/day; p = 0.87). The intervention improved EORTC role functioning domain (17 points; p = 0.022) with borderline improvement in dyspnea (− 13 points; p = 0.051) compared to UC. In patients with two blood samples (25%), we observed a significant increase in soluble PD-1 (219.8 (SD 54.5) pg/mL; p < 0.001). Conclusions Our pilot trial using a 3-month, home-based, mobile health intervention enrolled over half of eligible patients with stage III and IV NSCLC. The intervention increased PA, and may improve several aspects of QoL. We also identified potential biomarker changes relevant to lung cancer biology. Future research should use a larger sample to examine the effect of exercise on cancer biomarkers, which may mediate the association between PA and QoL. Clinical trial registration Clinicaltrials.gov (NCT03352245).

Download Full-text